| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.
|
N Engl J Med
|
2004
|
9.72
|
|
2
|
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial.
|
Lancet Infect Dis
|
2013
|
3.30
|
|
3
|
A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update.
|
Clin Gastroenterol Hepatol
|
2008
|
2.97
|
|
4
|
Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study.
|
J Hepatol
|
2007
|
2.58
|
|
5
|
Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study.
|
Gastroenterology
|
2004
|
2.28
|
|
6
|
Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial.
|
Ann Intern Med
|
2013
|
2.25
|
|
7
|
Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B.
|
Clin Gastroenterol Hepatol
|
2007
|
2.16
|
|
8
|
Interferon alfa-2b [correction of alpha-2b]and ribavirin for patients with chronic hepatitis C and normal ALT.
|
Am J Gastroenterol
|
2004
|
2.12
|
|
9
|
A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update.
|
Clin Gastroenterol Hepatol
|
2006
|
1.92
|
|
10
|
Liver fibrosis during an outbreak of acute hepatitis C virus infection in HIV-infected men: a prospective cohort study.
|
J Infect Dis
|
2008
|
1.78
|
|
11
|
A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin.
|
Gastroenterology
|
2010
|
1.70
|
|
12
|
A treatment algorithm for the management of chronic hepatitis B virus infection in the United States.
|
Clin Gastroenterol Hepatol
|
2004
|
1.47
|
|
13
|
Diabetes mellitus and advanced liver fibrosis are risk factors for severe anaemia during telaprevir-based triple therapy.
|
Liver Int
|
2013
|
1.43
|
|
14
|
Sustained virologic response with short-course ribavirin and peginterferon treatment in 2 patients coinfected with HIV and HCV genotype 1.
|
AIDS Read
|
2006
|
1.38
|
|
15
|
Acute HIV seroconversion in a patient receiving pegylated interferon for treatment of hepatitis C.
|
AIDS Read
|
2003
|
1.38
|
|
16
|
Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy.
|
Hepatology
|
2004
|
1.30
|
|
17
|
Chronic hepatitis B: preventing, detecting, and managing viral resistance.
|
Clin Gastroenterol Hepatol
|
2008
|
1.29
|
|
18
|
Hepatitis Outreach Network: a practical strategy for hepatitis screening with linkage to care in foreign-born communities.
|
J Hepatol
|
2013
|
1.25
|
|
19
|
Risk of immune recovery uveitis in patients with AIDS and cytomegalovirus retinitis.
|
Ophthalmology
|
2006
|
1.20
|
|
20
|
Short communication: Inadequate vitamin D exacerbates parathyroid hormone elevations in tenofovir users.
|
AIDS Res Hum Retroviruses
|
2010
|
1.08
|
|
21
|
Mortality in hepatitis C virus-infected patients with a diagnosis of AIDS in the era of combination antiretroviral therapy.
|
Clin Infect Dis
|
2012
|
1.08
|
|
22
|
Interferon-induced depression and cognitive impairment in hepatitis C virus patients: a 72 week prospective study.
|
AIDS
|
2005
|
1.08
|
|
23
|
Costs of telaprevir-based triple therapy for hepatitis C: $189,000 per sustained virological response.
|
Hepatology
|
2014
|
1.05
|
|
24
|
Acute pancreatitis associated with interferon and ribavirin therapy in patients with chronic hepatitis C.
|
Dig Dis Sci
|
2004
|
1.04
|
|
25
|
Management of hepatitis C virus in special populations: patient and treatment considerations.
|
Clin Gastroenterol Hepatol
|
2005
|
1.01
|
|
26
|
Toxicity of non-nucleoside analogue reverse transcriptase inhibitors.
|
Semin Liver Dis
|
2003
|
1.00
|
|
27
|
Effect of baseline CD4 cell count on the efficacy and safety of peginterferon Alfa-2a (40KD) plus ribavirin in patients with HIV/hepatitis C virus coinfection.
|
J Acquir Immune Defic Syndr
|
2008
|
0.97
|
|
28
|
HIV and liver diseases: recent clinical advances.
|
Clin Liver Dis
|
2005
|
0.96
|
|
29
|
Intrahepatic CD4+ cell depletion in hepatitis C virus/HIV-coinfected patients.
|
J Acquir Immune Defic Syndr
|
2004
|
0.95
|
|
30
|
Management of chronic hepatitis C virus in patients with HIV.
|
Curr Treat Options Gastroenterol
|
2005
|
0.95
|
|
31
|
Clinical factors that predict noncirrhotic portal hypertension in HIV-infected patients: a proposed diagnostic algorithm.
|
J Infect Dis
|
2013
|
0.94
|
|
32
|
The development of hepatoportal sclerosis and portal hypertension due to didanosine use in HIV.
|
Virchows Arch
|
2010
|
0.93
|
|
33
|
HIV/hepatitis C virus-coinfected patients and cirrhosis: how to diagnose it and what to do next?
|
Clin Infect Dis
|
2013
|
0.93
|
|
34
|
Telaprevir in the treatment of acute hepatitis C virus infection in HIV-infected men.
|
Clin Infect Dis
|
2013
|
0.90
|
|
35
|
Lack of hepatotoxicity associated with nonnucleoside reverse transcriptase inhibitors.
|
J Acquir Immune Defic Syndr
|
2002
|
0.89
|
|
36
|
Rapid progression to decompensated cirrhosis, liver transplant, and death in HIV-infected men after primary hepatitis C virus infection.
|
Clin Infect Dis
|
2012
|
0.88
|
|
37
|
Genetic analysis of interferon induced thyroiditis (IIT): evidence for a key role for MHC and apoptosis related genes and pathways.
|
J Autoimmun
|
2013
|
0.87
|
|
38
|
Current status of the use of growth factors and other adjuvant medications in patients receiving peginterferon and ribavirin.
|
Rev Gastroenterol Disord
|
2004
|
0.86
|
|
39
|
The critical role of medication adherence in the success of boceprevir and telaprevir in clinical practice.
|
J Hepatol
|
2011
|
0.86
|
|
40
|
The era of direct-acting antivirals has begun: the beginning of the end for HCV?
|
Semin Liver Dis
|
2011
|
0.86
|
|
41
|
Epoetin alfa once weekly improves anemia in HIV/hepatitis C virus-coinfected patients treated with interferon/ribavirin: a randomized controlled trial.
|
J Acquir Immune Defic Syndr
|
2005
|
0.85
|
|
42
|
Baseline factors prognostic of sustained virological response in patients with HIV-hepatitis C virus co-infection.
|
AIDS
|
2007
|
0.85
|
|
43
|
Hepatic steatosis in HIV/HCV co-infected patients: correlates, efficacy and outcomes of anti-HCV therapy: a paired liver biopsy study.
|
J Hepatol
|
2008
|
0.85
|
|
44
|
Effect of switching to tenofovir with emtricitabine in patients with chronic hepatitis B failing to respond to an adefovir-containing regimen.
|
Eur J Gastroenterol Hepatol
|
2006
|
0.84
|
|
45
|
Alcoholic Hepatitis.
|
Curr Treat Options Gastroenterol
|
2004
|
0.84
|
|
46
|
HBV plus HCV, HCV plus HIV, HBV plus HIV.
|
Curr Gastroenterol Rep
|
2006
|
0.83
|
|
47
|
Insulin resistance predicts re-treatment failure in an efficacy study of peginterferon-α-2a and ribavirin in HIV/HCV co-infected patients.
|
J Hepatol
|
2010
|
0.82
|
|
48
|
Early-onset liver fibrosis due to primary hepatitis C virus infection is higher over time in HIV-infected men.
|
Clin Infect Dis
|
2012
|
0.82
|
|
49
|
Daily versus thrice-weekly interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected persons: a multicenter randomized controlled trial.
|
J Acquir Immune Defic Syndr
|
2004
|
0.81
|
|
50
|
HIV-hepatitis C virus co-infection in the era of direct-acting antivirals.
|
Curr HIV/AIDS Rep
|
2014
|
0.79
|
|
51
|
Cost-effectiveness of peginterferon alfa-2a (40kDa) plus ribavirin in patients with HIV and hepatitis C virus co-infection.
|
J Clin Virol
|
2006
|
0.79
|
|
52
|
Hepatitis C direct-acting antiviral agents: changing the paradigm of hepatitis C treatment in HIV-infected patients.
|
J Clin Gastroenterol
|
2014
|
0.79
|
|
53
|
Evaluation of hepatitis C virus as a risk factor for HIV-associated neuroretinal disorder.
|
Clin Infect Dis
|
2013
|
0.77
|
|
54
|
Septic bursitis, a potential complication of protease inhibitor use in hepatitis C virus.
|
Clin Infect Dis
|
2013
|
0.77
|
|
55
|
Treatment of hepatitis C virus in HIV patients: a review.
|
AIDS
|
2005
|
0.77
|
|
56
|
Hepatitis C screening beyond CDC guidelines in an Egyptian immigrant community.
|
Liver Int
|
2013
|
0.76
|
|
57
|
The HIV/HCV-coinfected patient and new treatment options.
|
Clin Liver Dis
|
2011
|
0.76
|
|
58
|
Update on combinations of DAAs with and without pegylated-interferon and ribavirin: triple and quadruple therapy more than doubles SVR.
|
Clin Liver Dis
|
2013
|
0.76
|
|
59
|
Hepatitis B: the immaculate infection.
|
Gastroenterol Hepatol (N Y)
|
2007
|
0.76
|
|
60
|
Treating HCV in HIV 2013: on the cusp of change.
|
Liver Int
|
2014
|
0.76
|
|
61
|
MELD score and antibiotics use are predictors of length of stay in patients hospitalized with hepatic encephalopathy.
|
BMC Gastroenterol
|
2014
|
0.75
|
|
62
|
Editorial comment: a tale of two viruses.
|
AIDS Read
|
2002
|
0.75
|
|
63
|
Editorial comment: liver disease in the HIV-infected patient--the courage to treat.
|
AIDS Read
|
2003
|
0.75
|
|
64
|
A great time to invest in baby Boomer's hepatitis C!
|
Hepatology
|
2012
|
0.75
|
|
65
|
Editorial comment: HIV and HBV coinfection--a coming-of-age in treatment strategies.
|
AIDS Read
|
2004
|
0.75
|
|
66
|
Trends in Liver Transplantation in Hepatitis C Virus-Infected Persons, United States.
|
Emerg Infect Dis
|
2016
|
0.75
|
|
67
|
Hepatitis B therapies and antiviral resistance detection and management.
|
Expert Rev Gastroenterol Hepatol
|
2009
|
0.75
|
|
68
|
Interferon-free regimens for hepatitis C: combine and conquer.
|
BioDrugs
|
2014
|
0.75
|
|
69
|
Management and diagnosis of fatty liver disease.
|
Expert Rev Gastroenterol Hepatol
|
2015
|
0.75
|
|
70
|
Pegylated-IFNα2a for HIV/hepatitis C virus coinfected patients: out with the old, in with the new.
|
Expert Opin Biol Ther
|
2014
|
0.75
|
|
71
|
Antiretroviral and anti-hepatitis C virus direct-acting antiviral-related hepatotoxicity.
|
Clin Liver Dis
|
2013
|
0.75
|
|
72
|
The pharmacokinetic evaluation of boceprevir for treatment of hepatitis C virus.
|
Expert Opin Drug Metab Toxicol
|
2013
|
0.75
|
|
73
|
The challenge of hepatitis C and HIV co-infection.
|
Body Posit
|
2005
|
0.75
|
|
74
|
Hepatitis C management in HIV infection--where is the controversy?
|
AIDS Read
|
2002
|
0.75
|
|
75
|
Hepatitis C in HIV-infected patients: impact of direct-acting antivirals.
|
Drugs
|
2014
|
0.75
|
|
76
|
Treatment of acute hepatitis C in an HIV-positive man with pegylated interferon and ribavirin for 24 weeks.
|
AIDS Read
|
2007
|
0.75
|